- | F2G
What’s the future of health? SXSW panels talk AI, tech, personalized medicine and more
With global warming, fungi have become more adapted to higher temperatures like the human body, and with the use of fungicides in farming, fungi are more resistant to treatments.

- | F2G
Health experts at SXSW warn of possible untreatable global fungi outbreak
“Eighty percent of our crop pathogens are fungi,” said Dr. John Rex, chief medical officer for biotech company F2G. “If we’re going to produce crops, especially in these changing environmental conditions, we’re going to need fungicides.”

- | MindMed
FDA Grants Breakthrough Therapy Status To LSD Drug To Treat Anxiety
In a report on the research, the company said that a single oral dose of MM120 met its key secondary endpoint, maintaining “clinically and statistically

- | Elicio Therapeutics
The future of cancer immunotherapy with Elicio Therapeutics
AMP immunotherapy enhanced the infiltration and function of TCR-T cells in the tumour microenvironment and led to epitope spreading against diverse tumour targets. Long-term protection against tumour recurrence in AMP-treated mice was associated with antigen spreading to additional tumour-associated antigens not targeted by the treatment.

- | Recce Pharmaceuticals
James Graham: CEO of Recce Pharmaceuticals
James Graham, CEO of Recce Pharmaceuticals, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Recce is working to develop a new class of synthetic anti-infectives designed to address the threat of antibiotic-resistant superbugs.

- | Grifols
Grifols readies US, EU approval push for blood clot treatment after phase 3 success
Grifols is readying an approval run at U.S. and European regulators on the back of a phase 3 win for the Spanish plasma medicine producer’s concentrated form of a blood clotting factor.

- | Elicio Therapeutics
New Cancer Vaccines Could Treat Some Types of Pancreatic, Colorectal and Other Deadly Forms of the Disease
The trial included 25 people with pancreatic or colorectal cancer who had previously undergone surgery, seven of whom also had received radiation therapy. They were given up to 10 doses of the vaccine known as ELI-002, and the results were promising: 84 percent of all participants had positive T cell responses—and all of those who received higher doses had a response. The results of the trial, which was funded by Boston-based biotech company Elicio Therapeutics, were published in Nature Medicine.

- | Lumos Pharma
Rare Community Profiles: Dr. Pisit “Duke” Pitukcheewanont Discusses Phase 2 Results in LUM-201 for Pediatric Growth Hormone Deficiency
Lumos Pharma is developing LUM-201 (ibutamoren) for the treatment of moderate pediatric growth hormone deficiency. PGHD is a rare disorder in which the body doesn’t make enough growth hormone.